Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELIOS-A phase 3 study of ALN-TTRSC02 versus patisiran in hereditary transthyretin amyloidosis
NL-OMON52839Phase 3Active, not recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jan 2020
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hereditary transthyretin amyloidosis (hATTR) comparing ALN-TTRSC02 with patisiran then ALN-TTRSC02 extension (2 arms). Started Jan 2020; status: active, not recruiting.
02
Drugs
vutrisiranpatisiran
03
Conditions
hereditary transthyretin amyloidosis (hATTR)
Beyond the preview
Go deeper on NL-OMON52839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52839.